

## **Elelyso**

Prior Authorization Request
Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: 🗖 Same as Re	questing Provider
Name:	NPI#:
Fax:	Phone:
	ferring Provider 🗆 Same as Requesting Provider
Name:	
	Dhonos
Approvals may be subject accepted comp	Phone:  to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines.
accepted comp  Required Demographic Information:	to dosing limits in accordance with FDA-approved labeling endia, and/or evidence-based practice guidelines.
Approvals may be subject accepted comp	to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelineskg
Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:  Patient Height:	to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines. kgcm
Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:	to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines. kgcm requested drug:
Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the	to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines. kgcm requested drug:  \$\sim Home \square Off Campus Outpatient Hospital
Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the ☐ Ambulatory Surgical	to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines. kgcm requested drug:  \$\sim Home \square Off Campus Outpatient Hospital
Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the  Ambulatory Surgical  On Campus Outpatient Hospital  Drug Information:	to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines. kgcm requested drug: HomeOff Campus Outpatient HospitalOffice
Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the  Ambulatory Surgical  On Campus Outpatient Hospital  Drug Information:  Strength/Measure	to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines. kgkgcm requested drug:Home

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHCPP Elelyso MR Medicaid SGM 2053-A – 07/2023.

Exc	ception Criteria Questions:	
	Is the product being requested for the treatment of Gaucher disease type 1?  ☐ Yes ☐ No If No, skip to Criteria Questions	
B.	The preferred product for your patient's health plan is Cerezyme. Can the patient's treatment be switched to the preferred product? $\square$ Yes, <i>Please obtain Form for preferred product and submit for corresponding PA</i> $\square$ No	
C.	Does the patient have a documented inadequate response to treatment with the preferred product, Cerezyme? <i>ACTION REQUIRED: If 'Yes', attach supporting chart note(s).</i> $\square$ Yes, <i>skip to Criteria Questions</i> $\square$ No	
D.	Does the patient have a documented intolerable adverse event to the preferred product, Cerezyme? <i>ACTION REQUIRED: If 'Yes', attach supporting chart note(s).</i> $\square$ Yes $\square$ No	
<u>Cri</u>	iteria Questions:	
1.	What is the diagnosis?	
ſ	☐ Gaucher disease (If checked, go to 2)	
ſ	☐ Other, please specify(If checked, go to 2)	
gl su	Was the diagnosis of Gaucher disease confirmed by an enzyme assay demonstrating a deficiency of beta- ucocerebrosidase (glucosidase) enzyme activity or by genetic testing? <i>ACTION REQUIRED</i> : If Yes, attach apporting chart note(s) or test results.  Yes (If checked, go to 3)  No (If checked, go to 3)	
3.	Which variant of Gaucher disease does the patient have?	
	Type 1 (If checked, go to 4)	
	Type 2 (If checked, go to 4)	
	Type 3 (If checked, go to 4)	
	Other, please specify (If checked, go to 4)	
	Is this request for continuation of treatment with the requested drug?	
	Yes (If checked, go to 5)	
L	□ No (If checked, go to 6)	
	Is the patient experiencing an inadequate response or any intolerable adverse events from therapy with the quested drug?	
ſ	☐ Yes (If checked, go to 6)	
ſ	□ No (If checked, go to 6)	
6	What is the patient's body weight?	
	Less than or equal to 100 kg (220.5 lbs) (If checked, no further questions)	
	Greater than 100 kg (220.5 lbs) (If checked, no further questions)	
	ttest that this information is accurate and true, and that documentation supporting this formation is available for review if requested by Priority Partners.	
X_	Determination of Company	
rre	escriber or Authorized Signature Date (mm/dd/yy)	

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHCPP Elelyso MR Medicaid SGM 2053-A - 07/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076